Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Intentional product use issue? 2,913 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 2,913 reports of Intentional product use issue have been filed in association with TOFACITINIB (XELJANZ XR). This represents 1.9% of all adverse event reports for TOFACITINIB.

2,913
Reports of Intentional product use issue with TOFACITINIB
1.9%
of all TOFACITINIB reports
1,078
Deaths
1,435
Hospitalizations

How Dangerous Is Intentional product use issue From TOFACITINIB?

Of the 2,913 reports, 1,078 (37.0%) resulted in death, 1,435 (49.3%) required hospitalization, and 1,323 (45.4%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 2,913 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which TOFACITINIB Alternatives Have Lower Intentional product use issue Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue TOFACITINIB Demographics